Illustrative image.
Tevimbra
Tislelizumab‑jsgr
$4255.00
1 vial
BrandBranded medicine· By BeiGene
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
About Tevimbra
Overview
Tevimbra (tislelizumab-jsgr) is a prescription antibody medicine supplied in a vial for intravenous use. It treats adults with esophageal squamous cell cancer that cannot be surgically removed or has spread, either with platinum-containing chemotherapy as initial treatment for PD-L1-positive tumors, or alone after chemotherapy that did not include a PD-1 or PD-L1 inhibitor. It is also used as initial treatment with platinum- and fluoropyrimidine-based chemotherapy for PD-L1-positive, HER2-negative stomach or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread, and with zanidatamab-hrii plus that chemotherapy for HER2-positive stomach, gastroesophageal junction or esophageal adenocarcinoma that is locally advanced and cannot be surgically removed, or has spread. It works by blocking PD-1, helping release a brake on the immune system’s response to cancer.
What it treats
- Esophageal squamous cell carcinoma in adults that cannot be surgically removed or has spread: with platinum-containing chemotherapy as first-line treatment when tumors express PD-L1 (≥1), or alone after prior systemic chemotherapy that did not include a PD-1 or PD-L1 inhibitor. - HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults that cannot be surgically removed or has spread and expresses PD-L1 (≥1): with platinum- and fluoropyrimidine-based chemotherapy as first-line treatment. - HER2-positive (IHC 3+ or IHC 2+/ISH+) gastric, gastroesophageal junction or esophageal adenocarcinoma in adults that is locally advanced and cannot be surgically removed, or has spread: with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment.
Safety information
Side effects
Common side effects vary depending on whether Tevimbra is used alone or with other medicines. They include tiredness, reduced appetite, nausea, vomiting, diarrhea, mouth inflammation, abdominal pain, muscle or bone pain, cough, weight loss, fever, rash, and nerve problems affecting sensation. Common blood test changes include anemia, reduced white blood cells or platelets, increased blood sugar, changes in liver tests, increased creatinine, and low sodium, potassium, calcium or albumin. Contact your doctor promptly about possible serious side effects. Tevimbra can cause immune system reactions in any organ or tissue that may be severe or fatal. These include inflammation of the lungs, bowel, liver, kidneys or skin, problems with hormone-producing glands, and rejection of a transplanted organ. Liver, kidney and thyroid tests are needed before and during treatment. Depending on severity, treatment may need to be paused or permanently stopped. Reactions during an infusion may require the infusion to be slowed, interrupted or permanently stopped. Tell the healthcare team immediately if you experience a reaction during an infusion. Serious or fatal complications can occur in people who receive a stem cell transplant from a donor before or after treatment with this type of medicine. Tevimbra can also harm an unborn baby. Use effective contraception if you can become pregnant, and contact your doctor if you become pregnant.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The label lists no contraindications for Tevimbra. However, serious or fatal immune-related reactions can affect any organ or tissue, including the lungs, bowel, liver, hormone-producing glands, kidneys and skin. Rejection of a transplanted organ can also occur. Liver enzymes, kidney function and thyroid function should be checked before and periodically during treatment. Treatment may need to be paused or permanently stopped depending on the severity of a reaction. Infusion-related reactions may require slowing, interrupting or permanently stopping the infusion. Serious or fatal complications can occur in people who receive an allogeneic stem cell transplant before or after treatment with a PD-1/PD-L1 blocking antibody such as Tevimbra. Tevimbra can harm an unborn baby. People who can become pregnant should use effective contraception. Do not breastfeed during treatment.
Using Tevimbra
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label TEVIMBRA (TISLELIZUMAB-JSGR) INJECTION, SOLUTION, CONCENTRATE [BEONE MEDICINES USA, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00